Matching articles for "Adempas"
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • March 8, 2021; (Issue 1619)
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension and
chronic thromboembolic pulmonary hypertension,
was the first.
Selexipag (Uptravi) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • February 15, 2016; (Issue 1488)
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral...
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral prostacyclin analog,
was approved earlier for this indication.
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • January 4, 2016; (Issue 1485)
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this...
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this indication.
Riociguat (Adempas) for Pulmonary Hypertension
The Medical Letter on Drugs and Therapeutics • March 3, 2014; (Issue 1437)
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary...
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is not an
option. It is the first drug to be approved for treatment
of CTEPH.
Macitentan (Opsumit) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • February 17, 2014; (Issue 1436)
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist...
The FDA has approved macitentan (ma" si ten' tan; Opsumit
– Actelion), for oral treatment of pulmonary arterial
hypertension (PAH). Macitentan is the second nonselective
endothelin receptor antagonist approved for PAH. It is a derivative
of bosentan (Tracleer), which is also manufactured
by Actelion, and is scheduled to become available generically
in 2015. Riociguat (Adempas), another new drug for
this indication, will be reviewed in a future issue.
Volibris